TOI Q4 revenue $71M (+36.6% YoY), net loss narrows; beats revised 2022 guidance

Oncology Institute, Inc.

Q4 2022 revenue $71M (+36.6% YoY); gross profit $16M (+87.6% YoY); net loss $9.5M vs $10.2M prior year.
Adjusted EBITDA loss improved to $(4.6)M from $(5.6)M in Q4 2021.
Ended FY2022 with $132M cash; completed $110M Deerfield investment in Aug 2022.
Surpassed top end of revised 2022 guidance for revenue, gross profit, and adjusted EBITDA.
Market count expanded to 15 from 10; capitated membership added 100k+ lives.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Oncology Institute, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $71 million, net income $9.5 million, EPS $(0.11) and $(0.15).

Period: the fourth quarter ended December 31, 2022
Revenue: $71 million
Net income: $9.5 million
EPS: $(0.11) and $(0.15)
Result: reported results

Exact text from the filing

• Consolidated revenue of $71 million, an increase of 36.6% from $52 million compared to the prior year quarter • Gross profit of $16 million, an increase of 87.6% compared to the prior year quarter • Net loss of $9.5 million compared to net loss of $10.2 million for the prior year quarter • Basic and diluted earnings per share of $(0.11) and $(0.15), respectively, compared to $(0.13) for the prior year quarter

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Oncology Institute, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-007305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.